Evidence map›Paper›PMID 28633424›Full record

ArticleToxicological sciences : an official journal of the Society of Toxicology2017

From the Cover: Three-Dimensional (3D) HepaRG Spheroid Model With Physiologically Relevant Xenobiotic Metabolism Competence and Hepatocyte Functionality for Liver Toxicity Screening.

Sreenivasa C Ramaiahgari, Suramya Waidyanatha, Darlene Dixon, Michael J DeVito, Richard S Paules, Stephen S Ferguson

Erratum issuedAbstract read
In one paragraph

Article in Toxicological sciences : an official journal of the Society of Toxicology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Transferability and Reproducibility of the HepaRG CometChip Assay.Environmental and molecular mutagenesis · 2025
    Article
  6. Article
  7. In vitro liver models for toxicological research.Drug metabolism and pharmacokinetics · 2025
    Review
  8. Article
  9. HepaRGNAM journal · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Application of HepaRG cells for genotoxicity assessment: a review.Journal of environmental science and health. Part C, Toxicology and carcinogenesis · 2024
    Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Sreenivasa C RamaiahgariDivision of the National Toxicology Program, National Institute of Environmental Health Sciences, NIH, Durham, North Carolina 27709.
Suramya WaidyanathaDivision of the National Toxicology Program, National Institute of Environmental Health Sciences, NIH, Durham, North Carolina 27709.
Darlene DixonDivision of the National Toxicology Program, National Institute of Environmental Health Sciences, NIH, Durham, North Carolina 27709.
Michael J DeVitoDivision of the National Toxicology Program, National Institute of Environmental Health Sciences, NIH, Durham, North Carolina 27709.
Richard S PaulesDivision of the National Toxicology Program, National Institute of Environmental Health Sciences, NIH, Durham, North Carolina 27709.
Stephen S FergusonDivision of the National Toxicology Program, National Institute of Environmental Health Sciences, NIH, Durham, North Carolina 27709.

Funding

Toxicological Assessments for the National Toxicology ProgramZIAES103316 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI WALKER, NIGEL J · 2016 to 2019
$31.9M
Pathobiology Of Uterine Leiomyomas (fibroids)ZIAES021196 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI DIXON, DARLENE · 2009 to 2025
$31.7M
Biomolecular Screening and Alternative Approaches for the National Toxicology ProgramZIAES103318 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI CASEY, WARREN · 2016 to 2021
$25.0M
6 · The paper itself

Abstract

Effective prediction of human responses to chemical and drug exposure is of critical importance in environmental toxicology research and drug development. While significant progress has been made to address this challenge using invitro liver models, these approaches often fail due to inadequate tissue model functionality. Herein, we describe the development, optimization, and characterization of a novel three-dimensional (3D) spheroid model using differentiated HepaRG cells that achieve and maintain physiologically relevant levels of xenobiotic metabolism (CYP1A2, CYP2B6, and CYP3A4/5). This invitro model maintains a stable phenotype over multiple weeks in both 96- and 384-well formats, supports highly reproducible tissue-like architectures and models pharmacologically- and environmentally important hepatic receptor pathways (ie AhR, CAR, and PXR) analogous to primary human hepatocyte cultures. HepaRG spheroid cultures use 50-100× fewer cells than conventional two dimensional cultures, and enable the identification of metabolically activated toxicants. Spheroid size, time in culture and culture media composition were important factors affecting basal levels of xenobiotic metabolism and liver enzyme inducibility with activators of hepatic receptors AhR, CAR and PXR. Repeated exposure studies showed higher sensitivity than traditional 2D cultures in identifying compounds that cause liver injury and metabolism-dependent toxicity. This platform combines the well-documented impact of 3D culture configuration for improved tissue functionality and longevity with the requisite throughput and repeatability needed for year-over-year toxicology screening.

Indexed as

Models, BiologicalCell LineCytochrome P-450 Enzyme SystemHumansLiverSpheroids, CellularXenobioticsCytochrome P-450 Enzyme SystemXenobiotics3DHepaRG; nuclear receptorinvitrospheroidsxenobiotic metabolism

Identifiers

PMID28633424
PMCPMC5837526

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.